Parliamentary.ai

Overview

This bill aims to regulate physician associates (PAs) in the UK by establishing a register, a code of conduct, and licensing procedures, all overseen by the General Medical Council (GMC). It also makes "physician associate" a protected title, preventing unqualified individuals from using it.

Description

The bill designates the GMC as the regulatory body for PAs. Key responsibilities of the GMC include maintaining a register of qualified PAs, issuing licenses to practice, establishing and monitoring a code of conduct, and overseeing training and qualifications. The register will initially include those already on the Faculty of Physician Associates' voluntary register. The bill creates a criminal offense for falsely claiming to be a registered PA. The bill also mandates a report by the Professional Standards Authority for Health and Social Care (PSA) on the costs and benefits of PA regulation, including whether PAs should be allowed to prescribe medication or perform ionizing radiation procedures. The GMC must consult with relevant bodies before establishing rules and regulations for PAs.

Government Spending

The bill doesn't specify exact figures for government spending. However, costs will be incurred by the GMC in establishing and maintaining the PA register and regulatory framework. The PSA report will assess the overall costs and benefits of the regulation.

Groups Affected

• Physician Associates (PAs): This bill directly impacts PAs, requiring registration, licensing, adherence to a code of conduct, and ongoing professional development.
• General Medical Council (GMC): The GMC will bear the responsibility and associated costs of regulating PAs.
• Patients: Patients will benefit from increased assurance of PA competence and safety through regulation.
• Professional Standards Authority for Health and Social Care (PSA): The PSA is responsible for producing a report assessing the impact of the regulation.
• Faculty of Physician Associates at the Royal College of Physicians: This body will be consulted throughout the regulatory process.